Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in August

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at the following investor conferences in August:

• Wedbush 2015 Life Sciences Management Access Conference at 8:00 a.m. ET in New York on Tuesday, August 11, 2015.
• Canaccord Genuity’s 35th Annual Growth Conference at 9:00 a.m. ET in Boston on Wednesday, August 12, 2015.

Live audio webcasts of the Pacira presentations can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. Replays of the webcasts will be archived on the Pacira website for two weeks following the respective presentation dates.

About Pacira

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150803005111/en/

Pacira Pharmaceuticals, Inc.
Jessica Cho, 973-254-3574

Source: Pacira Pharmaceuticals, Inc.

You May Also Be Interested In

• Las Vegas Fabricator Expands Facility and Enters Nuclear Sector
• AI Can Help CIOs Reclaim Capacity as 83% of IT Spend and 66% of Staff Time Go Toward Keeping the Lights On, Says Info-Tech Research Group
• Moody’s Assigns First-Time Insurance Financial Strength Ratings to Freedom Insurance and Freedom Life